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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Noonan syndrome (NS) is inherited as an autosomal dominant disorder
with dysmorphic facies, short stature, and cardiac defects, which can be caused by missense
mutations in the protein tyrosine phosphatase nonreceptor type 11 (PTPN11) gene, which
encodes src homology region 2 domain containing tyrosine phosphatase-2 (SHP-2), a protein
tyrosine phosphatase that acts in signal transduction downstream to growth factors and cyto-
kines. The current study aimed to study the molecular characterization of the PTPN11 gene
among Egyptian patients with Noonan syndrome.
Methods: Eleven exons of the PTPN11 gene were amplified and screened by single stranded
conformational polymorphism (SSCP). DNA samples showing band shift in SSCP were subjected
to sequencing.
Results: Mutational analysis of the PTPN11 gene revealed T/C transition at position 854 in
exon 8, predicting Phe285Ser substitution within PTP domain of SHP-2 protein, in one NS
patient and e21C/T polymorphism in intron 7 in four other cases.
Conclusion: Knowing that NS is phenotypically heterogeneous, molecular characterization of
the PTPN11 gene should serve to establish NS diagnosis in patients with atypical features,
although lack of a mutation does not exclude the possibility of NS.
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Noonan syndrome (NS) [OMIM 163950] is an autosomal
dominant disorder clinically characterized by short stature,
facial dysmorphisms, webbed neck, congenital heart
defects, cryptorchidism in males and mild mental retarda-
tion.1,2 Although precise epidemiologic data are not avail-
able, the prevalence of NS is estimated to be between
1:1000 and 1:2500 live births.3 Tartaglia et al4 have shown
that missense mutations in the PTPN11 (protein-tyrosine
phosphatase, nonreceptor type 11) gene on chromosome 12
(12q24) account for approximately 50% of NS cases. PTPN11
encodes the nonreceptor protein tyrosine phosphatase SHP-
2, which is a member of a small subfamily of cytosolic
protein tyrosine phosphatases (PTPs).4 These proteins
exhibit a high degree of homology in amino acid sequence
and share a common structure composed of two amino-
terminal src-homology 2 (SH2) domains (N-SH2 and
C-SH2), a PTP, and a carboxy-terminal tail.5 The SHP-2 is
ubiquitously expressed and involved in mesodermal
patterning,6 limb development,7 hematopoietic cell
differentiation8 and semilunar valvulogenesis.9 The PTPN11
is expressed in various tissues and plays a critical role in
regulating the responses of eukaryotic cells to multiple
extracellular signals, such as hormones, cytokines, and
growth factors. Activation of SHP-2 results from binding of
the N-SH2 domains to short amino acid motifs containing
a phosphotyrosyl residue.10 Crystallographic data on SHP-2
indicate that the N-SH2 domain interacts with the PTP
domain in the inactive conformation, blocking the catalytic
site.11 After the N-SH2 domain binds a phosphotyrosyl
residue, a conformational change that reduces the inter-
molecular interaction between the N-SH2 and PTP domains
makes the catalytic site available to substrate. Thus, the N-
SH2 domain acts as a molecular switch, activating and
inactivating SHP-2. The PTPN11 mutations that cause NS
clustered in the interacting portions of the N-SH2 and PTP
domains, and energetics-based structural analysis sug-
gested that these mutations would stabilize SHP-2 in the
active conformation. Thus, it was proposed that the PTPN11
mutations in NS induce a gain of function.4 The current
study investigated PTPN11 mutational patterns among
Egyptian NS patients.
Materials and methods
Clinical evaluation
The study protocol was approved by the Medical Research
Ethics Committee (MREC) of the National Research Center
(NRC). Twenty-one Egyptian patients (12 males) were
recruited from the clinical genetics clinics in NCR. Ages
of patients ranged from 2 to 20 years. The patients under-
went a detailed physical and clinical assessment, which
included anthropometric measurements, abdominal ultra-
sound, spine X-ray, and ophthalmologic and hematologic
examination. Pubertal stage (genitalia in males, breast in
females and pubic hair in both sexes) was evaluated by the
classification of Tanner scale.12 Dysmorphic features were
evaluated clinically and cardiac anomalies were diagnosed
based on either echocardiography or cardiac catheterizationfindings. NSwas diagnosed on the basis of the presence of the
following major characteristics: typical facial dysmorphia,
cardiac anomalies, height <2 SD below the mean13
and cryptorchidism in male subjects. To have a diagnosis
of NS, individuals with typical facial dysmorphia had to
have at least one additional major feature, whereas indi-
viduals with suggestive facial findings had to have at least
two other major characteristics.14 Ten clinically normal
individuals ofmatchedageand sexwere included in the study
and served as control group. Informed written consent
was obtained from all participants or their parents.
Mutational analysis
Screening of the exons for sequence variants was per-
formed by PCR amplification followed by single stranded
conformational polymorphism (SSCP) and DNA sequencing.
Polymerase chain reaction
Genomic DNA was extracted from peripheral blood
lymphocytes of patients and controls by phenol/chloroform
method.15 Eleven exons of the PTPN11 gene were screened
for mutations. The PCRs were performed in a 50 ml reaction
volume containing 1 ng genomic DNA, 1.6U DyNAzyme Taq
(Finnzyme, Espoo, Finland), 40 pmol each primer, 0.25 mM
each dNTP, 5 ml buffer using thermocycler (Biometra, Go¨t-
tingen, Germany). For exons 2 to 8, 12, and 13) the PCR
cycling condition was: 95C for 3 minutes, followed by 45
cycles of 95C for 30 seconds, 56C to 60C for 30 seconds,
and 68C for 90 seconds, finishing with 7 minutes at 68C.16
Exons 10 and 11 amplifications were: 92C for 3 minutes,
then 35 cycles of 94C for 30 seconds, 51C for 60 seconds,
and 72C for 30 seconds, ending with 10 minutes at 70C.17
Primer pairs were designed to amplify exons, exon/intron
boundaries, and short intron flanking stretches. Primer
sequences, annealing temperatures, and sizes of PCR
products are listed in Table 1.16,17
SSCP
The PCR products were screened for mutation by the SSCP
technique, which is based on differences in nucleotide
sequence (often a single base pair) resulting in variable
secondary structures. An 8 ml aliquot of PCR product was
mixed with an equal volume of denaturing-loading buffer,
heated at 95C for 10 minutes, then immediately placed in
ice for 5 minutes and loaded onto a 7% nondenaturing
polyacrylamide gel (16 15 1.5 cm). Samples were run at
400 V for 3 hours at 4C. After electrophoresis, the gel was
stained using SILVER SEQUENCE DNA Sequencing System
(Promega, Madison, Wisconsin, USA).
DNA sequencing
DNA samples showing a band shift in SSCP were subjected to
DNA sequencing. The PCRproductswere purifiedbyQiaQuick
PCR purification kit (Qiagen, Valencia, CA, USA) . Sequencing
of each sample was performed with ABI Big Dye Terminator
Cycle sequencing chemistry and the products were analyzed
on an ABI 310 DNA sequencer (Applied Biosystems,
Table 1 Primer pairs and annealing temperatures used to amplify PTPN11 gene and sizes of PCR products.
Exon Primer sequence (50/30) Annealing temp (C) Product length (bp)
Exon 2 F ACT GAA TCC CAG GTC TCT ACC AAG 60 405
R CAG CAA GCT ATC CAA GCA TGG T
Exon 3 F CGA CGT GGA AGA TGA GAT CTG A 60 384
R CAG TCA CAA GCC TTT GGA GTC AG
Exon 4 F AGG AGA GCT GAC TGT ATA CAG TAG 58 447
R CAT CTG TAG GTG ATA GAG CAA GA
Exon 5 F CTG CAG TGA ACA TGA GAG TGC TTG 60 329
R GTT GAA GCT GCA ATG GGT ACA TG
Exon 6 F TGC ATT AAC ACC GTT TTC TGT 54 282
R GTC AGT TTC AAG TCT CTC AGG TC
Exon 7 F GAA CAT TTC CTA GGA TGA ATT CC 56 271
R GGT ACA GAG GTG CTA GGA ATC A
Exon 8 F GAC ATC AGG CAG TGT TCA CGT TAC 57 350
R CCT TAA AGT TAC TTT CAG GAC ATG
Exon 12 F GCT CCA AAG AGT AGA CAT TGT TTC 56 250
R GAC TGT TTT CGT GAG CAC TTT C
Exon 13 F CAA CAC TGT AGC CAT TGC AAC A 60 356
R CGT ATC CAA GAG GCC TAG CAA G
Exon 10 F TTC TGA TCT CTT CCA GA 50.5 246
R ATG CAT GCA TGT ATG CA
Exon 11 F AAG CTT AGA ACC GGG TGA 50.5 319
R AAG AGC TAG GAG TGG GTA
Exons 2e8, 12, and 13 amplifications were performed according to the method of Tartaglia et al,16 and those for exons 10 and 11 were
conducted as described by Bertola et al.17 F Z forward; R Z reverse.
Table 2 Clinical features of all NS patients.
Clinical findings Frequency, n (%)
Male 12 (57)
Female 9 (43)
Parental consanguinity 6 (29)
Facial features 21 (100)
Broad or high forehead 16 (76)
Hypertelorism 21 (100)
Downward slanting of palpebral fissure 21 (100)
Ptosis 6 (29)
Webbed/short neck 21 (100)
Ear low set/posterior rotated 12 (57)
Chest wall abnormalities 17 (81)
Pectus craniatum/excavatum 8 (38)
Broad chest 15 (71)
Cardiac abnormalities 15 (71)
Hypertrophic cardiomyopathy 4 (19)
Valvular pulmonary stenosis 5 (24)
Other cardiac defects 6 (29)
Cryptorchidism (undescended testis) 4/12 (33)
Short stature (<2.0 SD) 15 (71)
Mental retardation (IQ < 75) 11 (52)
Hypotonia 6 (29)
Joint hyperextensibility 4 (19)
Hepatomegaly 2 (10)
IQ Z intelligence quotient.
Mutational analysis of PTPN11 gene 709Foster City, CA, USA). The sequencing chromatograms
were compared with the corresponding wild type using
sequence analysis software (Applied Biosystems).
Results
Clinical features
Clinical features of all NS patients are shown in Table 2.
Mutation analysis of the PTPN11 gene
The study included amplification of 11 exons of the PTPN11
gene to be screened for pointmutation and then sequencing.
Screening of PCR products of the PTPN11 gene by
SSCP
SSCP analysis for each of the 11 exons of the PTPN11 gene
was performed and the abnormal migration pattern was
observed in exon 8 in one case (Fig. 1) and four other cases
where only three patients were presented (Fig. 2).
DNA sequencing
Direct sequencing was performed for all samples that
showed different SSCP patterns compared to the normal
controls. Sequencing chromatogram revealed T/C transi-
tion at position 854 in exon 8 in only one case (Fig. 3), while
four patients demonstrated e21C/T polymorphism in
intron 7 (Fig. 4).
Figure 1 SSCP analysis of exon 8 of the PTPN11 gene. Lanes
1, 2, 5: normal control samples with the wild type sequence of
exon 8. Lanes 3, 4: one patient showing shift in the migration
pattern of the upper band of exon 8.
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In the present study, sequencing chromatograms of the
PTPN11 gene revealed mutations in 4.7%, in addition to the
e21C/T polymorphism in intron 7 in 19% of the patients
who had classic features of Noonan syndrome. Phenotypic
features of PTPN11 mutation-negative cases were compa-
rable to those of the mutation-positive cases. The variation
in mutation rate reported in the present work and that
reported in other studies16,18,19 might be referred to the
difference in the technique used for mutation screening
and/or to the possibility of genetic heterogeneity in this
disorder. In line with the current results, previous studies
suggested that one or more other genes are responsible for
most of the remainder of the cases diagnosed clinically as
NS but did not show a detectable mutation in the PTPN11
gene.4,18 The only reported mutation in our study was the
T/C transition at position 854 in exon 8, predicting the
Phe285Ser substitution within the PTP domain of SHP2
protein. This mutation has been previously reported in
a Japanese,18 a Brazilian,17 and an Italian20 patient.
Furthermore, Levaillant et al21 reported that the identifi-
cation of a 854 T/C mutation in the PTPN11 gene ascertain
a severe Noonan phenotype in prenatally examined French
fetus as many of the major symptoms overlap in both
Costello and severe Noonan syndromes. Interestingly, theFigure 2 SSCP analysis of exon 8 of the PTPN11 gene. Lanes
1, 2, 3, 4, 6, 7, 8, 9: normal control samples with the wild type
sequence of exon 8. Lanes 5, 10, 11: three patients showing
shift in the migration pattern of the upper band of exon 8.same codon has changes in the flanking nucleotides 853 and
855. A 853 T/C leading to Phe285Leu has been reported in
one patient by Tartaglia et al,16 whereas a familial case has
been identified, in which the amino acid substitution,
Phe285Ileu, detected in two brothers, was inherited from
the mother.20 Regarding nucleotide 855, Hung et al22
identified a novel mutation 855 T/G (Phe285Leu) in 1/34
Taiwanese patient with NS. Hence, it seems that the 854
codon might be a hotspot for mutation.
Attempts to elucidate genotype-phenotype correlations
have been done by several authors,16,19,23,24 but definite
conclusions have not been established. Considering that not
all cases of NS are due to mutation of PTPN11, it would be
interesting and possibly useful to find a way to distinguish
the phenotype of the PTPN11 cases from NS due to other
causes. In some of the previous studies,16,24 pulmonary
stenosis was more prevalent in the group with PTPN11 gene
mutations. On the other hand, hypertrophic cardiomyop-
athy was less prevalent in the group with an alteration in
PTPN11. 16 However, Sarkozy et al 19 did not find a differ-
ence in the frequency of this heart defect between the two
groups. In our present analysis, we also did not find this
association.
All of the PTPN11 mutations detected have been
heterozygous single base substitutions. Mutations were
clustered in 7 exons (2, 3, 4, 7, 8, 12, and 13).25 In fact,
exons 3, 8, and 13 harbor 86% of the mutations.17 In their
cohort, Papadopoulou et al 26 reported that the most
prevalent mutation was 188 A/G in exon 3 (5/17 cases)
while 922 A/G in exon 8, 802 G/2A mutation in exon 7,
and 1510 A/G in exon 13 had the same frequency (2/17) in
Greek patients. The A/G transition at position 922 in exon
8, predicting the Asn308Asp substitution within the PTP
domain, was not found in the cohort study of Bertola
et al,17 in contrast to 31% in the study of Tartaglia et al,16
suggesting that this mutation is not as prevalent in the
Brazilian population as compared to the North American
population. Musante et al23 showed that the most common
mutation reported by Tartaglia et al,16 an A/G transition
at position 922 in exon 8, was present in four patients of his
study, thus representing only 17% of the total number of
mutations identified. The occurrence of the adjacent 923
A/G mutation, predicting an Asn308Ser change, indicated
that codon 308 represents a hotspot for NS.16
All the base changes that resulted in amino acid substi-
tutions within the subregions of the N-SH2 and PTP
domains, where the two domains interact, lead to negative
regulation of the phosphatase activity of the protein.5
Hence, missense mutations in these subregions would
disrupt the intramolecular interaction between the N-SH2
and the PTP domain, leading to a conformational change
into a constitutively active form. Of particular interest is
the observation that SH2 normally down-regulates growth
hormone signaling.27 Constitutive activation of SH2 might
cause GH hyporesponsiveness and give rise to the short
stature and growth delay observed in NS. Indeed, incom-
plete clinical response to exogenous GH has been docu-
mented in NS28 and might result from a combination of
deleterious effects of SH2 on GH signaling and other path-
ways. Crystallographic data on SHP-2 in the inactive
conformation revealed a complex interdomain hydrogen-
bonding networkdinvolving Asn58, Gly60, Asp61, Cys459,
Figure 3 Sequencing chromatograms of the PTPN11 gene showing (A) wild-type pattern for exon 8 and (B) one NS patient having
T/C substitution at position 854 in exon 8.
Mutational analysis of PTPN11 gene 711and Gln506dthat stabilizes the protein.11 Numerous polar
interactions between N-SH2 residues located in strands bF
and bA, helix aB, and residues of the PTP domain further
stabilize the inactive conformation. Significantly, most of
the residues mutated in NS are either directly involved in
these interdomain interactions (i.e., Gly60, Asp61, Ala72,
Glu76, and Gln79) or in close spatial proximity to them
(i.e., Tyr62, Tyr63, Thr73, Tyr279, Ile282, Phe285, Asn308,
Ile309, Arg501, and Met504). This distribution of molecular
lesions suggests that the pathogenetic mechanism in NS
involves altered N-SH2/PTP interactions that destabilize
the inactive conformation without altering SHP-2’s cata-
lytic capability. Consistent with this view, no mutation
altered Cys459 (the residue essential for nucleophilic
attack), the PTP signature motif (Positions 457e467), or the
TrpProAsp loop (Positions 423e425), which are all essential
for phosphatase activity.16 Musante et al23 demonstratedFigure 4 Sequencing chromatograms of thePTPN11 gene showing (
of intron 7.that the transition G/C at position 417 in exon 4
(Glu139Asp) is the only mutation identified that alters an
amino acid in the C-SH2 domain. Although the C-SH2
domain alone is unlikely to contribute to activation,11 there
is evidence that the C-SH2 domain contributes to the
substrate specificity and to the binding affinity.10 Binding of
the C-SH2 domain to a phosphotyrosine-containing ligand
could increase the local ligand concentration so that the N-
SH2 domain can bind a second site and adopts the active
conformation.
In conclusion, the T/C transition at position 854 in exon
8, predicting the Phe285Ser substitution within the PTP
domain of SHP2 protein, was the only reported mutation in
our cohort. The variant profile for this mutation was not
observed in control chromosomes. Although great progress
in the understanding of the etiology of NS has been ach-
ieved in recent years, it is still a challenging disorder, dueA)wild-type pattern for intron 7 and (B)e21C/Tpolymorphism
712 M.L. Essawi et al.to it being phenotypically heterogeneous. However, better
management and improved genetic counseling have already
been attained due to advanced molecular genetic testing.References
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